With two projects related to COVID-19 vaccine development in China, SAUTER strengthens its position as a global specialist in the field of pharmaceutical and laboratory control.
Rigorous requirements for critical sites such as laboratories and medical facilities are essential. Building management systems (BMS) not only ensure that the air flow is reliably maintained, they also prevent particle exchange between different areas within facilities and thus ensure a sterile environment.
Due to the outbreak of the current coronavirus in China and its huge impact on society and daily life, the Chinese government undertook massive efforts to respond to epidemics. Thereby, directed by the central government, the establishment of a national bio-security system, as well as the construction of new facilities related to biosafety labs were initiated.
Since the beginning of 2019, SAUTER took an early step on the Chinese market by investing in seminars and customer relationships which could lead to project opportunities. In China, SAUTER is known as the leading brand in the field of pharmaceutical and laboratory control. Based on worldwide life science references as well as a first successful project certified Animal Biological Safety Level 3 (ABSL3, meeting the specifications of Biosafety Level 3 facilities as well as additional requirements) in Lanzhou, SAUTER was entrusted with two further projects in Beijing.
The first project, a vaccine production plant run by the China National Pharmaceutical Group (Sinopharm), was completed earlier this year with a total area of more than 1,700 square metres. SAUTER installed the entire BMS system with 1,300 data points in 43 rooms, 12 of which are operated under negative pressure. The entire cleanroom area on the first floor is operated in positive pressure. SAUTER provided detailed design, installation, testing and commissioning as well as support for the Biosafety Level 3 (BSL-3) certification process.
According to Chinese media reports “the world’s biggest COVID-19 vaccine manufacturing plant achieved construction and certification in Beijing within 60 days”.
The second and larger project related to COVID-19 vaccine development is owned by Beijing Sinovac Research & Development Co. Ltd. and Sinovac Biotech Co. Ltd. The facility’s construction is currently on-going with an estimated number of data points of more than 4,500. Similar to the Sinopharm project, SAUTER’s scope of work includes detailed design, installation, testing and commissioning as well as support for the BSL-3 certification of the laboratory.
With the execution of the two projects related to COVID-19 vaccine development in China, SAUTER was once again able to demonstrate its expertise in the implementation of biosafety laboratory installations and could further strengthen its position as a global specialist. In China, the highly qualified SAUTER team continues to be recommended as a preferred BMS supplier by the Chinese Project Design Institute.
As the leading provider of solutions for building automation technology in Green Buildings, SAUTER ensures good climate conditions and a sense of well-being in sustainable environments. SAUTER is a specialist in developing, producing and marketing products and systems for energy-efficient total solutions, and offers a comprehensive range of services to ensure the energy-optimised operation of buildings. Our products, solutions and services enable high energy efficiency throughout the entire life-cycle of a building – from planning and construction through to operation – in office and administrative buildings, research and educational facilities, hospitals, industrial buildings and laboratories, airports, leisure facilities, hotels and data centres. With over 100 years’ experience and a track record of technological expertise, SAUTER is a proven system integrator that stands for continuous innovation and Swiss quality. SAUTER provides users and operators with an overview of energy flows and consumption, and therefore of the development of the costs involved.